

Board Renewal

Melbourne, Australia; 5 October 2022: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announces that as part of Starpharma's ongoing board renewal process non-executive director, Ms Zita Peach will not seek re-election at the upcoming Annual General Meeting and will retire at the conclusion of the meeting on 29 November 2022.

Ms Peach has been a non-executive director of Starpharma for 11 years, and her retirement is part of the Board's renewal process and follows a transition period after the appointment of Dr Jeff Davies as an independent non-executive director with extensive healthcare experience on 1 April 2022.

Starpharma's Chairman, Mr Robert Thomas AO, paid tribute to Ms Peach's substantial contribution. "Zita Peach has made an invaluable contribution to Starpharma's growth and development during her tenure, particularly as Chair of the Remuneration & Nomination Committee, and her fellow directors sincerely thank Zita for her detailed pharmaceutical industry and commercial insights and commitment."

Ms Peach said, "I would like to thank the Starpharma Board and Management team for their dedication. It has been a rewarding experience seeing the technology turn into marketed products and the exciting future pipeline being developed."

Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.

Mr Thomas added "Starpharma is fortunate to have Dr Davies join the Starpharma Board, with his deep expertise in the pharmaceutical industry over 35 years, and track record of bringing highly successful products to market. Dr Davies' skills and broad expertise in R&D, regulatory affairs, clinical research, commercialisation and operations will be of great value to Starpharma through its next phase of growth following the retirement of Ms Peach."

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP[®] drug delivery and VivaGel[®]. Starpharma has developed VIRALEZE[™], an antiviral nasal spray that is registered for sale in >30 countries. VIRALEZE[™] is not approved for sale or supply in Australia. SPL7013 is also utilised in the following products - the VivaGel[®] condom and VivaGel[®] BV. VivaGel[®] products have been licensed in >160 countries and are registered in >45 countries, including the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP[®], is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP[®] versions of existing drugs, particularly in the area of anti-cancer therapies. DEP[®] partnerships include oncology programs with AstraZeneca, with MSD in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Partnered DEP[®] programs have the potential to generate significant future milestones and royalties.

**Media: Sumit Media**

Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704

investor.relations@starpharma.com

4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Board of Directors.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", "outlook", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.